Market Report, "Biocon: Biosimilars Company Analysis", published

Oct. 18, 2012 - PRLog -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.

Scope
* Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
* Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/449050_biocon_biosimilars_company_analysis.aspx
------------------------------------------------------------

Highlights

Biocon's aspirations of expanding from its strong position in the Indian diabetes market were dashed when Pfizer pulled out of an insulin biosimilars deal in March 2012. It remains to be seen to what extent Biocon can continue development alone, or whether a replacement partner will be secured.

Reasons to Get this Report

* See how Biocon already holds a strong position in its domestic insulin antidiabetics market, and a growing presence in the wider biosimilars field
* Evaluate Biocon's marketing capabilities outside of India

Report Table of Contents:

ABOUT THIS REPORT

* Chapter structure

* Strategic insight
* Product analysis
* Operating performance
* Company introduction

* Data sourcing

* Analyst consensus

* PharmaVitae Explorer database

EXECUTIVE SUMMARY

* Biocon biosimilars overview
* Biocon biosimilars SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

STRATEGIC INSIGHT

* Biocon to extend existing alliances and seek out new partners
* Biocon to leverage in-house end-to-end development capabilities

KEY PRODUCTS

* Overview
* Biocon biosimilar portfolio
* Basalog, insulin aspart, and insulin lispro

* Overview
* Insulin glargine, lispro, and aspart global market size
* Key competitors
* Biocon biosimilar development

* Insugen (human insulin)

* Overview
* Insulin human market size
* Key competitors
* Biocon biosimilar development

* Erypo (epoetin alfa)

* Overview and market size
* Key competitors

* NUFIL and pegfilgrastim

* Overview
* Filgrastim and pegfilgrastim market size
* Key competitors

* Bmab-200 (trastuzumab)

* Overview
* Trastuzumab market size
* Key competitors
* Biocon biosimilar development

CORPORATE STRUCTURE

* Background
* Key corporate developments and company structure
* Deals and alliances

* Biocon and Pfizer conclude partnership
* Biocon and Mylan
* Biocon's other biosimilar-related deals

* Recent developments

APPENDIX

* References

* Datamonitor reports

* Exchange rates

TABLES

* Table: Biocon - biosimilar and novel biologic portfolio
* Table: Forecasted lispro, aspart, and glargine insulin sales in the seven major markets and ROW ($m), 2011-16
* Table: Biosimilar insulin aspart, insulin glargine, and insulin lispro products currently launched or in development
* Table: Biocon - biosimilar insulin glargine clinical trials
* Table: Forecasted human insulin sales in the seven major markets and ROW ($m), 2011-16
* Table: Biosimilar human insulin products currently launched or in development
* Table: Biocon - biosimilar human insulin clinical trials
* Table: Forecasted epoetin sales in the seven major markets and ROW ($m), 2011-16
* Table: Biocon - pipeline and marketed biosimilar epoetin drugs
* Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011-16
* Table: Biocon - pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs
* Table: Forecasted trastuzumab sales in the seven major markets and ROW ($m), 2011-16
* Table: Biosimilar trastuzumab drugs, 2012
* Table: Biocon - biosimilar trastuzumab clinical trials
* Table: Biocon - biosimilar related deal activities
* Table: Exchange rates, 2012

FIGURES

* Figure: The PharmaVitae Explorer
* Figure: Biocon biosimilars overview
* Figure: Biocon SWOT analysis
* Figure: Biocon biosimilars development capabilities
* Figure: Biocon - corporate structure

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.